Editorial: Will H. Pylori stagger under the weight of this LOAD a novel but expensive eradication regimen

American Journal of Gastroenterology

Volumn 106, Issue 11, 2011, Pages 1976-1977

  Watson, James B ^a   Moss, Steven F ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLARITHROMYCIN PLUS LANSOPRAZOLE; CLARITHROMYCIN; DOXYCYCLINE; LEVOFLOXACIN; METRONIDAZOLE; NITAZOXANIDE; OMEPRAZOLE; TINIDAZOLE; ANTIINFECTIVE AGENT; ANTIULCER AGENT; PROTON PUMP INHIBITOR;

DRUG COST; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; OPEN STUDY; PRIORITY JOURNAL; REVIEW; FEMALE; MALE; NOTE;

ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; PROTON PUMP INHIBITORS;

EID: 80655149507     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.309     Document Type: Review

References (10)

1. Brown LM. H elicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev 2000; 22: 283-97. (Pubitemid 32116099)
2. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-53.
3. Malfertheiner P, Bazzoli F, Delchier JC et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given withomeprazole vs. clarithromycin-based tripletherapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377: 905.
4. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-25. (Pubitemid 47206706)
5. Gatta L, Vakil N, Leandro G et al. Sequential therapy or tripletherapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009; 104: 3069-79.
6. Greenberg ER, Anderson GL, Morgan DR et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomized trial. Lancet 2011; 378: 507-14.
7. Duck WM, Sobel J, Pruckler JM et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004; 10: 1088-94. (Pubitemid 38697703)
8. Basu P, Rayapudi K, Pacana T et al. A randomized study comparing levofl oxacin, omeprazole, nitazoxanide, and doxycycline versus tripletherapy for the eradication of Helicobacter pylori. Am J Gastroenterol 2011;106:1970-5 (this issue).
9. Vakil N. H elicobacter pylori: factors aff ecting eradication and recurrence. Am J Gastroenterol 2005; 100: 2393.
10. Hung KH, Sheu BS, Chang WL et al. Prevalence of primary fl uoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter 2009; 14: 61-5.